Arvinas Inc (Arvinas) is a biopharmaceutical company that develops protein degradation therapeutics. The company develops novel therapeutics for the treatment of neuroscience, oncology, and other therapeutic areas. Its pipeline product includes ARV-471 for breast cancer, bavdegalutamide (ARV-110) for prostate cancer, and ARV-766 for the treatment of men with mCRPC. Arvinas’s protein degradation technology platform PROTAC Discovery Engine develops proteolysis-targeting chimera, or PROTAC-targeted protein degraders, and addresses a broad range of intracellular disease targets. The company intends to expand its transformative protein degradation technology and its product candidates into clinical development through collaborations with pharmaceutical companies. Arnivas is headquartered in New Haven, Connecticut, the US.
Headquarters
United States of America
Address
5 Science Park, New Haven, Connecticut, 06511-1966
Website
www.arvinas.com
Telephone
1 203 5351456
No of Employees
445
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ARVN (NASD)
Revenue (2022)
$78.5M
-40.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-30%
(2022 vs 2021)
Market Cap*
$2.3B
Net Profit Margin (2022)
XYZ
-117.6%
(2022 vs 2021)
* As of and is in US$
Arvinas Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | PROTAC |
| Bavdegalutamide (ARV-110) | |
| ARV-766 | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In April, the company entered into an agreement with Novartis to develop and commercialize ARV-766, Arvinas’ second-generation PROTAC androgen receptor degrader designed for individuals with prostate cancer. |
| 2023 | Contracts/Agreements | In July, the company and Pfizer announced a clinical trial collaboration and supply agreement with Carrick Therapeutics for execution of a Phase 1b/2 clinical trial to evaluate the novel combination of Carrick’s samuraciclib (CT7001). |
| 2023 | Contracts/Agreements | In May, the company and Quantum Leap Healthcare entered into an agreement with Pfizer to evaluate Vepdegestrant in I-SPY-2 endocrine optimization platform clinical trial. |
Competitor Comparison
| Key Parameters | Arvinas Inc | AbbVie Inc | Sanofi | Novartis AG | AstraZeneca Plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | France | Switzerland | United Kingdom |
| City | New Haven | North Chicago | Paris | Basel | Cambridge |
| State/Province | Connecticut | Illinois | Ile-de-France | - | England |
| No. of Employees | 445 | 50,000 | 87,994 | 76,057 | 89,900 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| John G. Houston, Ph.D. | Chairman; Chief Executive Officer; President | Executive Board | 2023 | - |
| Sean Cassidy | Chief Financial Officer; Treasurer | Senior Management | 2013 | 53 |
| David Loomis | Chief Accounting Officer; Controller; Vice President | Senior Management | - | - |
| Noah Berkowitz, M.D., Ph.D. | Chief Medical Officer | Senior Management | 2024 | - |
| Ian Taylor, Ph.D. | Chief Scientific Officer | Senior Management | 2019 | 60 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward